livemint.com
40%
657
Tocilizumab cuts covid risks but may not benefit Cipla
Cipla Ltd may not gain much from a UK trial showing that tocilizumab significantly reduces the risk of death when given to hospitalized patients with severe covid-19, analysts said. Cipla is the only distributor of the drug in India under the brand Actemra through a partnership with its innovator F.